Noninvasive imaging of hypoxia, hypoxia response and drug delivery : a bridge towards individualized patient treatment
作者： L. Dubois
DOI:
关键词:
摘要: Imaging (PET/CT scan) in cancer patients is an increasingly important element both diagnosis and treatment. Hypoxia (lack of oxygen) characteristic tumours that causes resistance against treatments. For efficient treatment hypoxia it to know which extent where present a tumour. This dissertation shows the possibility determining reaction cell low oxygen tension non-invasive way. We also proved imaging useful follow absorption medication cancer. will ultimately lead increased chance survival by quicker better selection for specific
narcis.nl参考文章(73)
Andrew Katsifis, Donna S Dorow, Gerald Reischl, Carleen Cullinane, Peter Roselt, David Binns, Rodney J Hicks, Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences. ,vol. 10, pp. 203- ,(2007)
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
Morand Piert, Maria Picchio, Leonard I. Wiebe, Gerald Reischl, Piyush Kumar, Hans Jürgen Machulla, Hans Jürgen Wester, Sybille Ziegler, Markus Schwaiger, Roswitha Beck, Alexander J B McEwan, Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside The Journal of Nuclear Medicine. ,vol. 46, pp. 106- 113 ,(2005)
Bernd Gagel, Patrick Reinartz, Cengiz Demirel, Hans J Kaiser, Michael Zimny, Marc Piroth, Michael Pinkawa, Sven Stanzel, Branka Asadpour, Kurt Hamacher, Heinz H Coenen, Ulrich Buell, Michael J Eble, [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study BMC Cancer. ,vol. 6, pp. 51- 51 ,(2006) , 10.1186/1471-2407-6-51
M. P.S. Dunphy, J. S. Lewis, Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET The Journal of Nuclear Medicine. ,vol. 50, ,(2009) , 10.2967/JNUMED.108.057281
Ernestina Schipani, Hypoxia and HIF-1α in chondrogenesis Seminars in Cell & Developmental Biology. ,vol. 16, pp. 539- 546 ,(2005) , 10.1016/J.SEMCDB.2005.03.003
Mohamed Hebbar, Agne`s Wacrenier, Christophe Desauw, Olivier Romano, Ste??phane Cattan, Jean-Pierre Triboulet, Francois-Rene?? Pruvot, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs. ,vol. 17, pp. 855- 857 ,(2006) , 10.1097/01.CAD.0000217425.44584.9F
Jesper G. Eriksen, Torben Steiniche, Jens Overgaard, The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study Radiotherapy and Oncology. ,vol. 74, pp. 93- 100 ,(2005) , 10.1016/J.RADONC.2004.12.018
Remco de Bree, Dirk J. Kuik, Jasper J. Quak, Jan C. Roos, Michiel W. M. van den Brekel, Jonas A. Castelijns, Frank W. van Wagtendonk, Henri Greuter, Gordon B. Snow, Guus A. M. S. van Dongen, The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 25, pp. 1562- 1565 ,(1998) , 10.1007/S002590050336
Iris Verel, Gerard W. M. Visser, Maria J. W. D. Vosjan, Ronald Finn, Ronald Boellaard, Guus A. M. S. van Dongen, High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 31, pp. 1645- 1652 ,(2004) , 10.1007/S00259-004-1632-8